Anna Brown

How pharma is reacting to ‘Liberation Day’: Join us tomorrow for Post-Hoc Live! Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to Trump administration tariffs, including lobbying & manufacturing changes.

Here's something new: our first-ever Post-Hoc Live happens tomorrow at noon ET

Watch @drewsnews.bsky.social, @maxbayer.bsky.social and @annajbrown.bsky.social talk pharma & tariffs — while live!

endpts.com/how-pharma-i...

J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.

Johnson & Johnson CEO Joaquin Duato subtly but assertively criticized President Donald Trump's plans for pharmaceutical tariffs, saying tax policy is a better way to onshore US drug manufacturing.

endpts.com/jj-ceo-chide...

Trump pledges his support for a change to the IRA long sought by drugmakers Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, and includes 340B program changes for EpiPens and insulin.

While Trump has launched a 232 investigation to tax pharmaceuticals, he's simultaneously issued an executive order to lower US drug prices. See @zacharybrennan.bsky.social coverage on this at @endpts.com: endpts.com/trump-pledge...

Pharma tariffs could leave little room to hide with sweeping probe underway A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Pharma tariffs are likely to leave little room to hide for companies as the 232 investigation hits all the major parts of the supply chain: endpts.com/trumps-pharm...

Pharma tariffs: Here’s what a potential rollout could look like Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible. China's API exports to US could face major impact.

Yesterday I wrote a piece for @endpts.com on what Trump's potential tariff rollout could look like for pharmaceuticals: endpts.com/pharma-tarif...

But CDMOs seem more concerned with the current FDA staff cutbacks delaying inspections: endpts.com/cdmos-antici...

Former FDA Commissioner:

Breaking: Firings sweep across FDA, gutting leadership and whole offices Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal health agencies being implemented by the Trump administration.

🚨 Breaking: Firings swept across the FDA, gutting leadership and whole offices, as some staff found out their jobs were cut when they showed up to work on Tuesday.
endpts.com/firings-swee...

Three major questions on pharma tariffs Trump claims are on the way Trump threatens pharma tariffs on foreign-made drugs, particularly targeting Ireland. Industry faces potential $63B annual tariff increase per PwC. Eli Lilly, J&J, AstraZeneca boost US investment.

Ahead of potential pharmaceutical tariffs next week, @maxbayer.bsky.social broke down what this could mean for the industry @endpts.com:

endpts.com/trump-pharma...

DOGE terminates lease on FDA quality lab in St. Louis, and 29 other sites DOGE says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based lab that operates under the FDA's Office of Pharmaceutical Quality.

DOGE terminates lease on FDA pharma quality lab in St. Louis that employs about 70 scientists - unclear on their fate endpts.com/doge-shutter...

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment WASHINGTON — Eli Lilly touted a huge new US manufacturing investment at an event on Wednesday, trotting out the news with a member of President Donald Trump’s cabinet as part of ...

Endpoints weekly manufacturing newsletter's out today, leading with our story on Lilly's $27 billion manufacturing push in the US from @zacharybrennan.bsky.social

endpts.com/lilly-says-i...

We are too! DM me or find me on Signal at zacharybrennan.20

Some FDA medical device staff reinstated just days after receiving pink slips Some of the more than 200 staffers laid off at the FDA's Center for Devices and Radiological Health (CDRH) returned to work Monday, about a week after hearing their roles would be cut, several device ...

Some of the user fee-funded staff at FDA were reinstated on Monday, after being laid off about a week ago for dubious reasons. 183 of the 230 staffers initially let go were supported by the user fee program endpts.com/some-fda-med...

Amanda Pritchard quits as NHS England chief executive in shock move Exclusive: Departure follows meetings with Wes Streeting and unusual criticism from two Commons committees Amanda Pritchard is standing down as chief executive of NHS England, in a development that will shock the health service. Her departure from the…

Amanda Pritchard quits as NHS England chief executive in shock move

Trump Cuts Target Next Generation of Scientists and Public Health Leaders A core group of so-called disease detectives, who track outbreaks, was apparently spared. But other young researchers are out of jobs.

Young scientists, doctors, and public health professionals who earned prestigious federal fellowships are getting the axe from Trump. Is this how to plan for the next pandemic?

“We owe them a debt of gratitude, not a pink slip,” former agency heads said.

www.nytimes.com/2025/02/18/u...

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on Tuesday, as top industry leaders took the stage and tried out some new mes...

Pfizer CEO Bourla: “Do I think we can convince them to do something bold in vaccines with Kennedy in HHS? Probably not. But do I think that we can convince them to do something very bold for cancer or for cardiovascular diseases with Kennedy in HHS? Absolutely I do.”
endpts.com/pfizer-ceo-s...

BREAKING: Nonprofits sue over Trump's anti-diversity, anti-trans executive orders, alleging they violate the First Amendment & equal protection guarantees, are void for vagueness, exceed the president's authority, & violate the Administrative Procedure Act. storage.courtlistener.com/recap/gov.us...

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has

Hello! Still in the process of moving over to Bluesky, for new friends: I write about biomanufacturing and supply chains over at @endpts.com -- feel free to reach out at abrown@endpointsnews.com for tips or just to say hi!

A taster of some manufacturing news today:

endpts.com/pfizers-manu...

We’ve seen this movie before.

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has

Pfizer’s contract manufacturing arm operates 12 facilities in Europe. CEO Albert Bourla warned that the business could be vulnerable to tariffs on European imports proposed during Donald Trump’s presidency.